No significant weaknesses identified
| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| VSEEWVSee Health, Inc. | 1.52M | 0.09 | -0.02 | 78.42% | -85.76% | |||
| VSEEVSee Health, Inc. | 14.7M | 0.44 | -0.08 | 80.74% | -85.76% | |||
| MGRXMangoceuticals, Inc. | 10.82M | 0.66 | -0.15 | -15.81% | -42.45% | -126.03% | 0.02 | |
| BEATHeartBeam, Inc. | 75.78M | 2.20 | -3.01 | -50.79% | ||||
| OMDAOmada Health | 906.26M | 15.65 | -18.41 | 38.29% | -16.82% | -16.98% | 0.47 | |
| HNGEHinge Health, Inc. | 1.66B | 43.76 | -291.73 | 33.37% | -3.06% | -2.83% | 2.73% | 0.03 |
| Dec 2023 | Dec 2024 | |
|---|---|---|
| Sales/Revenue | 292.73M | 390.4M |
| Revenue Growth % | - | 0.33% |
| Cost of Goods Sold | 98.55M | 89.81M |
| COGS % of Revenue | 0.34% | 0.23% |
| Gross Profit | 194.18M | 300.59M |
| Gross Margin % | 0.66% | 0.77% |
| Gross Profit Growth % | - | 0.55% |
| Operating Expenses | 324.69M | 325.02M |
| OpEx % of Revenue | 1.11% | 0.83% |
| Selling, General & Admin | 214.63M | 227.53M |
| SG&A % of Revenue | 0.73% | 0.58% |
| Research & Development | 110.06M | 97.49M |
| R&D % of Revenue | 0.38% | 0.25% |
| Other Operating Expenses | 0 | 0 |
| Operating Income | -130.51M | -24.43M |
| Operating Margin % | -0.45% | -0.06% |
| Operating Income Growth % | - | 0.81% |
| EBITDA | -124.89M | -18.48M |
| EBITDA Margin % | -0.43% | -0.05% |
| EBITDA Growth % | - | 0.85% |
| D&A (Non-Cash Add-back) | 5.63M | 5.95M |
| EBIT | -108.55M | -11.26M |
| Net Interest Income | 0 | 0 |
| Interest Income | 0 | 0 |
| Interest Expense | 0 | 0 |
| Other Income/Expense | 21.97M | 13.17M |
| Pretax Income | -108.55M | -11.26M |
| Pretax Margin % | -0.37% | -0.03% |
| Income Tax | -405K | 677K |
| Effective Tax Rate % | 1% | 1.06% |
| Net Income | -108.14M | -11.93M |
| Net Margin % | -0.37% | -0.03% |
| Net Income Growth % | - | 0.89% |
| Net Income (Continuing) | -108.14M | -11.93M |
| Discontinued Operations | 0 | 0 |
| Minority Interest | 0 | 0 |
| EPS (Diluted) | -1.39 | -0.15 |
| EPS Growth % | - | 0.89% |
| EPS (Basic) | -1.39 | -0.15 |
| Diluted Shares Outstanding | 78.02M | 78.02M |
| Basic Shares Outstanding | 78.02M | 78.02M |
| Dividend Payout Ratio | - | - |
| Dec 2023 | Dec 2024 | |
|---|---|---|
| Total Current Assets | 529.88M | 583.45M |
| Cash & Short-Term Investments | 423.36M | 466.57M |
| Cash Only | 234.95M | 300.79M |
| Short-Term Investments | 188.4M | 165.79M |
| Accounts Receivable | 46.56M | 42.49M |
| Days Sales Outstanding | 58.06 | 39.73 |
| Inventory | 13.29M | 10.87M |
| Days Inventory Outstanding | 49.23 | 44.19 |
| Other Current Assets | 32.31M | 39.59M |
| Total Non-Current Assets | 92.65M | 89.81M |
| Property, Plant & Equipment | 22.48M | 16.99M |
| Fixed Asset Turnover | 13.02x | 22.98x |
| Goodwill | 61.61M | 61.61M |
| Intangible Assets | 2.19M | 1.81M |
| Long-Term Investments | 0 | 0 |
| Other Non-Current Assets | 6.38M | 9.41M |
| Total Assets | 622.53M | 673.26M |
| Asset Turnover | 0.47x | 0.58x |
| Asset Growth % | - | 0.08% |
| Total Current Liabilities | 184.16M | 249.3M |
| Accounts Payable | 0 | 0 |
| Days Payables Outstanding | - | - |
| Short-Term Debt | 0 | 0 |
| Deferred Revenue (Current) | 1000K | 1000K |
| Other Current Liabilities | 6.37M | 4.16M |
| Current Ratio | 2.88x | 2.34x |
| Quick Ratio | 2.81x | 2.30x |
| Cash Conversion Cycle | - | - |
| Total Non-Current Liabilities | 11.1M | 7.26M |
| Long-Term Debt | 0 | 0 |
| Capital Lease Obligations | 11.1M | 7.26M |
| Deferred Tax Liabilities | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 |
| Total Liabilities | 195.25M | 256.56M |
| Total Debt | 15.73M | 11.07M |
| Net Debt | -219.22M | -289.71M |
| Debt / Equity | 0.04x | 0.03x |
| Debt / EBITDA | - | - |
| Net Debt / EBITDA | - | - |
| Interest Coverage | - | - |
| Total Equity | 427.28M | 416.7M |
| Equity Growth % | - | -0.02% |
| Book Value per Share | 5.48 | 5.34 |
| Total Shareholders' Equity | 427.28M | 416.7M |
| Common Stock | 0 | 0 |
| Retained Earnings | -510.8M | -522.74M |
| Treasury Stock | 0 | 0 |
| Accumulated OCI | 60K | 68K |
| Minority Interest | 0 | 0 |
| Dec 2023 | Dec 2024 | |
|---|---|---|
| Cash from Operations | -63.91M | 49M |
| Operating CF Margin % | -0.22% | 0.13% |
| Operating CF Growth % | - | 1.77% |
| Net Income | -108.14M | -11.93M |
| Depreciation & Amortization | 5.63M | 5.95M |
| Stock-Based Compensation | 1.65M | 739K |
| Deferred Taxes | -473K | -585K |
| Other Non-Cash Items | 28.02M | 41.33M |
| Working Capital Changes | 9.41M | 13.5M |
| Change in Receivables | -23.13M | -1.34M |
| Change in Inventory | 10.56M | 608K |
| Change in Payables | 0 | -10.97M |
| Cash from Investing | 1.5M | 18.31M |
| Capital Expenditures | -1.98M | -1.04M |
| CapEx % of Revenue | 0.01% | 0% |
| Acquisitions | - | - |
| Investments | - | - |
| Other Investing | -2.64M | -2.73M |
| Cash from Financing | -3M | -2.2M |
| Debt Issued (Net) | - | - |
| Equity Issued (Net) | - | - |
| Dividends Paid | 0 | 0 |
| Share Repurchases | - | - |
| Other Financing | -3M | -2.81M |
| Net Change in Cash | - | - |
| Free Cash Flow | -68.52M | 45.23M |
| FCF Margin % | -0.23% | 0.12% |
| FCF Growth % | - | 1.66% |
| FCF per Share | -0.88 | 0.58 |
| FCF Conversion (FCF/Net Income) | 0.59x | -4.11x |
| Interest Paid | 0 | 0 |
| Taxes Paid | 0 | 0 |
| Metric | 2023 | 2024 |
|---|---|---|
| Return on Equity (ROE) | -25.31% | -2.83% |
| Return on Invested Capital (ROIC) | -47.05% | -10.94% |
| Gross Margin | 66.33% | 77% |
| Net Margin | -36.94% | -3.06% |
| Debt / Equity | 0.04x | 0.03x |
| FCF Conversion | 0.59x | -4.11x |
| Revenue Growth | - | 33.37% |
Hinge Health, Inc. (HNGE) reported $390.4M in revenue for fiscal year 2024. This represents a 33% increase from $292.7M in 2023.
Hinge Health, Inc. (HNGE) grew revenue by 33.4% over the past year. This is strong growth.
Hinge Health, Inc. (HNGE) reported a net loss of $11.9M for fiscal year 2024.
Hinge Health, Inc. (HNGE) has a return on equity (ROE) of -2.8%. Negative ROE indicates the company is unprofitable.
Hinge Health, Inc. (HNGE) generated $45.2M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.